Posted by Michael Wonder on 17 Nov 2020
TRACON Pharmaceuticals announces submission for approval of envafolimab (KN035) with the NMPA in China by its corporate partners Alphamab Oncology and 3D Medicine
16 November 2020 - TRACON Pharmaceuticals today announced its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug application for the approval of envafolimab (KN035) in the indication of MSI-H/dMMR cancer to the National Medical Products Administration.
Envafolimab (KN035), a novel, single-domain antibody against PD-L1, is the first subcutaneously injected PD-(L)1 inhibitor to be studied in registration trials.
